DNMT3A and acute myeloid leukemia: The presence of ARCH was associated with a clearly increased risk of developing AML: Particularly, mutations in IDH1, IDH2, TP53 (tumor protein 53), DNMT3A, TET2, and spliceosome genes increased the risk of developing AML; increased progression to AML was seen for those with >1 mutated gene by targeted sequencing (increased complexity) and 10% variant-allele fraction; interestingly, all patients with TP53 or IDH1/IDH2 mutations developed AML [12].